March 5, 2020 / 12:24 PM / a month ago

BRIEF-Mallinckrodt - Adults With Biopsy-Proven Lgan At High Risk Of Progression To End-Stage Renal Disease, Acthar Gel Treatment Showed Reduction In Proteinuria

March 5 (Reuters) - Mallinckrodt Plc:

* MALLINCKRODT - ADULTS WITH BIOPSY-PROVEN LGAN AT HIGH RISK OF PROGRESSION TO END-STAGE RENAL DISEASE, ACTHAR GEL TREATMENT SHOWED REDUCTION IN PROTEINURIA

* MALLINCKRODT PLC - TREATMENT WITH ACTHAR GEL DEMONSTRATING A REDUCTION IN PROTEINURIA, WAS SUSTAINED AT 12 MONTHS

* MALLINCKRODT PLC - IN STUDY, MOST COMMON OTHER ADVERSE EVENTS WERE INJECTION REACTION, MUSCLE SORENESS, ACNE, HOT FLASHES, ANXIETY & INSOMNIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below